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1. Introduction 
The increasing morbidity due to peripheral artery disease (PAD) has given rise to a recent 
focus in cardiovascular medicine, and strategies for peripheral intervention have 
proliferated. For example, distal bypass, and catheter intervention for below-knee arteries 
have been performed aggressively. Also, there has been detailed research on the mortality of 
peripheral artery disease. In fact, it is reported that the mortality of PAD is higher than that 
of colon cancer. In a the patient with complicated PAD, even leg amputation does not prevent 
adverse events (Cruz, 2003; Aulivola, 2004). In this context, the discovery of other options for 
peripheral intervention is an impending. Also, patients may have various other diseases or a 
condition underlying the ischemic insult. Among these, vasculitis and collagen disease are 
often associated with difficult ischemic conditions. In these cases, there are limited options for 
treatment. Here we describe new techniques to achieve peripheral circulation including 
vascular angiogenesis, and explain the potential mechanism and effectiveness including that 
in vasculitis patients. 
2. Guidelines for peripheral artery disease 
Guidelines for peripheral artery disease have been published by the Trans Atlantic Inter-
Society Consensus (Hirsch, 2006). In these guidelines, a treatment strategy was precisely 
determined. However, there is still no established evidence regarding treatment for below-
knee arterial ischemia, especially for patients with critical limb ischemia (CLI), which is 
intractable limb ischemia due to PAD, who immediately face limb amputation. Catheter 
intervention and distal bypass grafting are well known to improve distal ischemia; however, 
however in specific conditions such as vasculitis or collagen disease, which is the focus of 
this chapter, the location of the occluded artery is mainly distal to the ankle or wrist which 
makes it difficult to treat with these strategies, and also, due to the pathogenesis of the 
original disease, the target vessels often become reoccluded soon after treatment. 
3. Diagnosis and definition of severity 
Definitive diagnosis should be made by documentation of the affected tissue. In order to 
make the correct diagnosis, biopsy of abnormal or symptomatic tissue is reliable. In patients 
with proven vasculitis, the diagnostic yield from biopsies of clinically normal sites is 
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considerably less than 20%. In addition, when a wound is complicated by vasculitis or 
collagen disease, the invasive nature of by biopsy itself worsens the wound, and it is usually 
difficult to obtain a tissue sample unless amputation tissue is available. 
In order to perform correct diagnosis and appropriate treatment, it is necessary to define the 
severity of ischemia using a reliable and safe method. Ankle-brachial index (ABI) is one of 
the useful screening methods for PAD. However, the data are inconsistent when the artery 
is severely calcified, which is known as Mönckeberg sclerosis (figure 1), which shows a 
pseudo-normalized value. Also, ABI is not a suitable method to define the amputation level. 
Skin perfusion pressure(SPP), obtained by digitized quantification of blood flow, is a 
reliable method that is also useful to define the amputation level. However, in vasculitis or 
collagen disease, it is difficult to apply because most patients experience excruciating pain, 
and cuff inflation may worsen the patient’s condition. Thus, there is no clear consensus 
regarding an evaluation method for CLI. One of the potential less invasive approaches to 
analyze blood flow level is, analyze radio-isotope imaging by 99mtechnetium-tetrofosmin 
(99mTc-TF) perfusion scintigraphy (Miyamoto, 2004). Furthermore, in consideration of 
repeatability, cost effectiveness, and minimum stimulation to the ischemic area, we propose 
transcutaneous oxygen tension (TcPO2) as the most useful method. It requires only electrode 
placement on the skin surface, and is suitable to examine distal ischemia even if the ischemic 
region is located below the ankle. The disadvantage of TcPO2 is the influence of the 
environment such as surrounding temperature or patient condition. In order to avoid 
possible error in detection, we propose that “maximum TcPO2” could clarify the result, and 
we believe the environmental influence could be minimized by data acquisition during 
100% oxygen inhalation (Tara, 2011a). 
 
 
Fig. 1. X-ray of leg. Representative case of Mönckeberg sclerosis. Vascular calcification and 
its location are well defined without contrast medium. 
4. Novel approach 
Due to pathogenesis of vasculitis, such as rheumatoid arthritis or collagen disease, vascular 
involvement mainly occurs in distal microvessels. Furthermore, the vasculitides are defined 
by the presence of an inflammatory process in the vessel wall, with reactive damage to 
mural structures. Often direct vascular stimulation by surgical or catheter intervention of 
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small vessels causes acute thrombosis or closure of the vessels. Also, according to the TASC 
guidelines, an intervention strategy has not been established for vasculitis. One of the recent 
topics is vascular regenerative therapy for PAD through the implantation of autologous 
bone marrow mononuclear cells into the ischemic area. In this context, the topic has been 
extended to secondary PAD due to vasculitis. In Japan, there has been a pilot study 
regarding bone marrow-derived stem cell implantation for collagen disease-related 
peripheral ischemia (Kamata, 2007; Takahashi, 2009). On the other hand, it was reported 
that endothelial progenitor cell function is inhibited, in collagen disease such as SLE patients 
treated with corticosteroids (Grisar, 2008), and also production of angiogenic factors from 
bone marrow cells is suppressed (Greenberger; Nauck, 1998). In addition, collected bone 
marrow would include a substantial amount of activated dendrocytes and immune 
stimulating cytokines such as interferon gamma which may worsen an ischemic ulcer. Thus, 
we focused on a more specific approach to vasculitis or collagen disease in order to establish 
a more safe and effective approach. 
5. Growth factor approach 
One strategy is to deliver recombinant proteins directly to the ischemic tissue by 
intramuscular or intraarterial injection. An alternate strategy is to use gene therapy, by 
direct transfer of expression vectors with either virus or naked plasmid. An optimal delivery 
strategy has not been established, and the approach of using a large amount of protein or 
gene as a therapeutic agent has several disadvantages. Also, the outcomes of early-phase 
clinical trials with a particular molecule have been less than encouraging, possibly because 
of factors such as the selection and formulation of the growth factor, duration of exposure, 
route of administration, and selection of patients. On the basis of our experiences, bone 
marrow mononuclear cell implantation in patients with complicated CLI is effective 
(Miyamoto, 2004). Regarding the mechanism, our colleague demonstrated potential 
cytokines produced from bone marrow mononuclear cells in response to ischemia (Uemura, 
2006). Among these growth factors such as basic fibroblast growth factor (b-FGF), vascular 
endothelial growth factor (VEGF), and  insulin-like growth factor (IGF), only b-FGF has a 
strong angiogenic property (Doi, 2007) and human recombinant b-FGF is available to 
purchase for clinical use in Japan. Furthermore, as b-FGF is a water soluble compound, 
Tabata et al (Tabata, 1998) developed a drug delivery system (DDS), utilizing b-FGF 
conjugated with gelatin hydrogel by chemical cross-linking that enables slow release of b-
FGF over two weeks. The precise method of gelatin hydrogel preparation (Figure 2) has 
been previously described (Tara, 2011b), in brief, gelatine microspheres were impregnated 
with an aqueous solution containing recombinant human b-FGF followed by leaving at 4 ºC 
for over 12 hours to obtain b-FGF-incorporated gelatine hydrogel. Under general anesthesia, 
we injected prepared b-FGF (600 μg)-incorporated gelatin hydrogel directly into the calf 
muscle at twenty sites around the ulcer under Doppler echo-guidance.  
 
 
Fig. 2. Gelatin microspheres. White bar indicates 20μm. 
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6. Our experience of novel treatment for vasculitis 
6.1 Churg-Strauss syndrome 
Churg-Strauss syndrome (CSS; allergic angitis and granulomatosis) is a rare syndrome that 
is occasionally complicated by cutaneous, and vascular involvement which shows 
characteristic histopathologic findings (Figure 3-A). Vasculitis involves the microcirculation, 
often with intractable cutaneous ulcers  (Figure 3-B), and when vascular involvement occurs 
at the visible artery level (Figure 3-C), standard corticosteroid treatment is less effective. 
Often the ulcer is complicated by antibiotics-resistant bacterial infection, which makes it 
difficult to continue or increase the corticosteroid dose. We injected 600μg b-FGF protein 
into the calf muscle, and the ulcer had healed 15 weeks later (Figure 3-D) (Kawanaka, 2009). 
6.2 Systemic lupus erythematosus (SLE) 
SLE is a systemic autoimmune disease characterized by the presence of immune complexes, 
autoantibodies and anti-nuclear antibody ANA), sometimes with cardiovascular 
involvement such as coronary arteritis or small arterial disease. Our case had an intractable 
ulcer above the lateral malleolus (Figure 4-A). Digital subtraction angiography revealed 
total occlusion of the right anterior tibial artery, right posterior tibial artery and right 
peroneal artery. The dorsalis pedis artery showed hardly any flow, and was supplied by 
collateral circulation (Figure 4-B). We injected 600μg b-FGF protein into the calf muscle and 
the ulcer had healed 4 weeks later (Figure 4-C) (Tara, 2011b). 
 
 
Fig. 3.A. Histological findings. Pathologic examination revealed vasculitis of small arteries 
and capillaritis with eosinophils as well as chronic inflammatory granulation-like changes in 
fibrous connective tissue. 
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Fig. 3. B. Patient with Churg-Strauss syndrome. Photographs show right lower calf ulcer 
that did not respond to topical and medical treatment. 
7. Discussion 
Among the vasculitides, we experienced cases of Churg-Strauss syndrome and SLE 
complicated by intractable ulcers. A DDS designed to provide controlled- release b-FGF 
protein mono-therapy successfully improved those ulcers and avoided major amputation. 
Leg ulcers complicate many conditions including ischemia and infection, and the location of 
ischemia varies among different diseases. Considering the pathogenesis of vasculitis, this 
protein - based angiogenesis therapy is less invasive, repeatable, safe and effective. 
Utilization of this DDS approach would be a powerful approach for vasculitis - related 
intractable ulcer. We recommend this controlled-release b-FGF protein therapy when the 
ulcer does not respond to usual corticosteroid therapy and when ischemia is documented 
angiographically. In the future, we plan to establish a multi-growth factor approach to 
enhance local circulation and wound healing in intractable ulcers. 
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Fig. 3. C. Digital subtraction angiographic findings. Total occlusion of the right superficial 
femoral artery is shown. 
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Fig. 4. A. Patient with SLE. The photograph shows a skin ulcer above the right lateral 
malleolus. 
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Fig. 4. B. Digital subtraction angiographic findings. Total occlusion of the right anterior tibial 
artery, right posterior tibial artery and right peroneal artery is shown. The dorsalis pedis 
artery was enhanced by collateral circulation 
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Fig. 4. C. SLE ulcer after treatment. The skin ulcer had healed completely 4 weeks after 
treatment. 
8. Conclusion 
Controlled-release b-FGF administration successfully healed ischemic skin ulcers and 
improved local skin blood perfusion in patients with vasculitis or collagen disease. Our 
findings suggest a novel clinical approach for ischemic skin ulcer associated with vasculitis 
or collagen disease. 
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